ReachMD

Episodes 1-11 of 11

• • 

    

    Michael Miller, MD, FACC, FAHA, FNLA

    Peer

  • 

    

    Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC

    Peer

  11

  

  RestartResume

  Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA

  Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA

  0.25 credits

• • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  • 

    

    James A. Underberg, MD, MS, FACP, FNLA

    Peer

  • 

    

    Nathan D. Wong, PhD

    Peer

  2

  

  RestartResume

  Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

  Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

  0.50 credits

• • 

    

    Javed Butler, MD, MBA, MPH

    Peer

  • 

    

    Paul W. Armstrong, MD

    Peer

  12

  

  RestartResume

  New Therapies Offer Improved Outcomes in HFrEF Management

  New Therapies Offer Improved Outcomes in HFrEF Management

  0.25 credits

• • 

    

    Jay S. Giri, MD, MPH

    Peer

  • 

    

    Renuka Jain, MD

    Peer

  5

  

  RestartResume

  New Opportunities to Manage Aortic Stenosis with TAVR

  New Opportunities to Manage Aortic Stenosis with TAVR

  0.50 credits

• • 

    

    Eliot Brinton, MD, FAHA, FNLA

    Peer

  • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  21

  

  RestartResume

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  0.75 credits

• • 

    

    Yehuda Handelsman, MD

    Peer

  • 

    

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    Peer

  • 

    

    Om P. Ganda, MD

    Peer

  • 

    

    Jorge Plutzky, MD

    Peer

  • 

    

    Paul D. Rosenblit, MD, PhD, FACE, FNLA

    Peer

  4

  

  RestartResume

  Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

  Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

• • 

    

    Michel Farnier, MD, PhD

    Peer

  • 

    

    Børge G. Nordestgaard, MD, DMSc

    Peer

  8

  

  RestartResume

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  0.75 credits

• • 

    

    Christopher P. Cannon, MD

    Peer

  • 

    

    Samuel Dagogo-Jack, MD, DSc

    Peer

  12

  

  RestartResume

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  0.25 credits

• • 

    

    Ewa A. Jankowska, MD, PhD, FESC

    Peer

  • 

    

    Stefan D. Anker, MD, PhD

    Peer

  16

  

  RestartResume

  Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

  Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

  0.25 credits

• • 

    

    Javed Butler, MD, MBA, MPH

    Peer

  8

  

  RestartResume

  Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy

  Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy

  0.25 credits

• • 

    

    Robert J. Mentz, MD

    Peer

  • 

    

    Piotr Ponikowski, MD, PHD, FESC, FHFA

    Peer

  15

  

  RestartResume

  Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency

  Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency

  0.25 credits